International Journal of Rheumatic Diseases · 2020 · 50 citations · 42 references
MedicineDermatologyClinical EpidemiologyEpidemiologic MethodsEpidemiologyChronic DiseaseSystemic SclerosisCohort Study InvestigationDiffuse Cutaneous Systemic SclerosisFibrosis In Systemic SclerosisGeneralized Estimating EquationsLimited Cutaneous Systemic SclerosisLongitudinal Cohort AnalysisLongitudinal Cohort StudiesMortality Rate Comparison
BACKGROUND: Most Thai patients with systemic sclerosis (SSc) have diffuse cutaneous SSc (dcSSc) unlike most Caucasians and some Asians. A longitudinal cohort study among Thai dcSSc is needed. OBJECTIVES: We aimed to determine the overall clinical characteristics, define the clinical difference between limited cutaneous SSc (lcSSc) and dcSSc, and ascertain the mortality rate and the factors associated with mortality. METHOD: We conducted a cohort study including 566 Thai adult SSc patients between January 2013 and June 2019. Clinical difference between lcSSc and dcSSc was investigated using generalized estimating equations (GEE). RESULTS: Females presented more than males (356 vs 210 cases). The majority of cases were dcSSc (411; 72.6%). The median duration of disease at the time of pulmonary fibrosis (PF) detection was 2.5 years, pulmonary arterial hypertension 8.1 years, and renal crisis 4.1 years. By GEE analysis, dcSSc was significantly associated with salt-and-pepper skin, hand deformity, and every 1-point increase in modified Rodnan skin score (mRSS). A greater mortality risk was associated with age at onset >60 years (hazards ratio [HR] 5.5), a World Health Organization functional class (FC) III (HR 5.1), FC IV (HR 34.8), edematous skin (HR 11.4), early onset of PF (HR 1.7), each 5-point increase in the mRSS (HR 4.5), and ≥2 internal organ involvements (HR 10.1). CONCLUSION: dcSSc is a common SSc subset among Thais. PF was an early complication in SSc and earlier PF detection was associated with a poorer prognosis. Elderly onset, high FC, severe skin tightness, and multiple organ involvements were associated with a greater mortality risk.
42
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
E. Carwile LeRoy, Casilda G. Black, Raúl Fleischmajer et al. · 2001 · 4K citations
Medicine, Pathobiology, Pathology +10
Cyclophosphamide versus Placebo in Scleroderma Lung Disease
Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text